Literature DB >> 35368394

Effects of cannabidiol without delta-9-tetrahydrocannabinol on canine atopic dermatitis: A retrospective assessment of 8 cases.

Chie Mogi1, Masanori Yoshida1, Koji Kawano1, Takaaki Fukuyama1, Toshiro Arai1.   

Abstract

Objective: We aimed to examine the effects of cannabidiol (CBD)-containing hemp oil without delta-9-tetrahydrocannabinol (THC) as a supplemental treatment for canine atopic dermatitis (CAD), as well as its adverse effects, and effects on concurrent drug use in dogs. Animal: In this retrospective case series, 8 dogs with CAD were diagnosed by veterinary dermatologists certified by the Japanese Society of Veterinary Dermatology. Procedure: The medical records of dogs supplemented with CBD-containing hemp oil were evaluated with respect to signalment, physical examination, plasma C-reactive protein concentrations, pharmacologic management, the CAD Extent and Severity Index (4th iteration), and the Pruritus Visual Analog Scale.
Results: Overall, CBD, used as a supplement in combination with other drugs, was well-tolerated over a wide dose range and decreased the occurrence of pruritus in dogs with CAD when ingested twice a day.
Conclusion: This study provides the first report of supplementation with CBD without THC that was effective in controlling pruritic behavior in dogs with CAD. Clinical relevance: Further controlled studies are required to investigate the dose range, efficacy, and safety. Copyright and/or publishing rights held by the Canadian Veterinary Medical Association.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35368394      PMCID: PMC8922375     

Source DB:  PubMed          Journal:  Can Vet J        ISSN: 0008-5286            Impact factor:   1.075


  12 in total

1.  Cannabinoid receptor type 1 and 2 expression in the skin of healthy dogs and dogs with atopic dermatitis.

Authors:  Luca Campora; Vincenzo Miragliotta; Emanuele Ricci; Luigia Cristino; Vincenzo Di Marzo; Francesco Albanese; Maria Federica Della Valle; Francesca Abramo
Journal:  Am J Vet Res       Date:  2012-07       Impact factor: 1.156

2.  Evaluation of Plasma C-Reactive Protein as a Biomarker in Dogs with Atopic -Dermatitis Receiving Allergen-Specific Immunotherapy: A Pilot Study.

Authors:  C Favrot; N Fischer; A Rostaher; T Olivry
Journal:  Schweiz Arch Tierheilkd       Date:  2021-01       Impact factor: 0.845

Review 3.  Cannabidiol: State of the art and new challenges for therapeutic applications.

Authors:  Simona Pisanti; Anna Maria Malfitano; Elena Ciaglia; Anna Lamberti; Roberta Ranieri; Gaia Cuomo; Mario Abate; Giorgio Faggiana; Maria Chiara Proto; Donatella Fiore; Chiara Laezza; Maurizio Bifulco
Journal:  Pharmacol Ther       Date:  2017-02-22       Impact factor: 12.310

4.  Further validation of a pruritus severity scale for use in dogs.

Authors:  J Rybnícek; P J Lau-Gillard; R Harvey; P B Hill
Journal:  Vet Dermatol       Date:  2009-12-19       Impact factor: 1.589

5.  Validation of the Canine Atopic Dermatitis Extent and Severity Index (CADESI)-4, a simplified severity scale for assessing skin lesions of atopic dermatitis in dogs.

Authors:  Thierry Olivry; Manolis Saridomichelakis; Tim Nuttall; Emmanuel Bensignor; Craig E Griffin; Peter B Hill
Journal:  Vet Dermatol       Date:  2014-01-25       Impact factor: 1.589

Review 6.  Cannabinoids and Cytochrome P450 Interactions.

Authors:  Ondřej Zendulka; Gabriela Dovrtělová; Kristýna Nosková; Miroslav Turjap; Alexandra Šulcová; Lumír Hanuš; Jan Juřica
Journal:  Curr Drug Metab       Date:  2016       Impact factor: 3.731

Review 7.  New concept of the pathogenesis of atopic dermatitis: interplay among the barrier, allergy, and pruritus as a trinity.

Authors:  Kenji Kabashima
Journal:  J Dermatol Sci       Date:  2013-02-15       Impact factor: 4.563

Review 8.  An update on the treatment of canine atopic dermatitis.

Authors:  Manolis N Saridomichelakis; Thierry Olivry
Journal:  Vet J       Date:  2015-09-16       Impact factor: 2.688

Review 9.  Potential Adverse Drug Events and Drug-Drug Interactions with Medical and Consumer Cannabidiol (CBD) Use.

Authors:  Joshua D Brown; Almut G Winterstein
Journal:  J Clin Med       Date:  2019-07-08       Impact factor: 4.241

10.  Assessment of Disease-Related Therapeutic Protein Drug-Drug Interaction for Etrolizumab in Patients With Moderately to Severely Active Ulcerative Colitis.

Authors:  Xiaohui Wei; Jane R Kenny; Leslie Dickmann; Romeo Maciuca; Caroline Looney; Meina T Tang
Journal:  J Clin Pharmacol       Date:  2016-01-11       Impact factor: 3.126

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.